Abstract | PURPOSE:
Androgens are essential for prostatic growth and development but they also have a significant role in prostate disease pathogenesis. Dihydrotestosterone, the primary prostatic androgen, is transformed from testosterone by types 1 and 2 5alpha-reductase and, thus, a potential therapeutic benefit could be achieved through the inhibition of 5alpha-reductase. MATERIALS AND METHODS: A literature review was performed using PubMed/MEDLINE and congress abstracts to examine evidence supporting the potential of 5alpha-reductase inhibitors in the primary prevention of prostate cancer and in limiting the progression of diagnosed disease. RESULTS: CONCLUSIONS: The inhibition of 5alpha-reductase represents a valid target for prostate cancer risk reduction and treatment strategies. The greater suppression of dihydrotestosterone observed with agents that inhibit each 5alpha-reductase isoenzyme may translate into enhanced outcomes and studies are under way to test this hypothesis.
|
Authors | Donald J Tindall, Roger S Rittmaster |
Journal | The Journal of urology
(J Urol)
Vol. 179
Issue 4
Pg. 1235-42
(Apr 2008)
ISSN: 1527-3792 [Electronic] United States |
PMID | 18280514
(Publication Type: Journal Article, Review)
|
Chemical References |
- 5-alpha Reductase Inhibitors
- Androgen Receptor Antagonists
- Azasteroids
- Enzyme Inhibitors
- Isoenzymes
- Receptors, Androgen
- Dihydrotestosterone
- Finasteride
- 3-Oxo-5-alpha-Steroid 4-Dehydrogenase
- Dutasteride
|
Topics |
- 3-Oxo-5-alpha-Steroid 4-Dehydrogenase
(metabolism)
- 5-alpha Reductase Inhibitors
- Androgen Receptor Antagonists
- Azasteroids
(therapeutic use)
- Dihydrotestosterone
(antagonists & inhibitors, metabolism)
- Disease Progression
- Dutasteride
- Enzyme Inhibitors
(therapeutic use)
- Finasteride
(therapeutic use)
- Humans
- Isoenzymes
(antagonists & inhibitors)
- Male
- Prostate
(metabolism)
- Prostatic Neoplasms
(drug therapy, metabolism, prevention & control, therapy)
- Receptors, Androgen
(metabolism)
|